Table 3 Proportion of patients with prolonged PT-INR at peak daptomycin concentration and the relative change of PT-INR between trough and peak
Reagent | PT-INRpeak > PT-INRtrough (%) | p valuea | PT-INRpeak/PT-INRtrough (95% CI) | p valueb |
|---|---|---|---|---|
1 | 26/35 (74%) | 0.006 | 1.05 (1.02–1.07) | 1.00 |
2 | 27/35 (77%) | 0.002 | 1.04 (1.01–1.07) | 1.00 |
3 | 31/35 (89%) | <0.001 | 1.07 (1.03–1.11) | 0.94 |
4 | 20/35 (57%) | 0.50 | 1.00 (0.98–1.02) | 1.00 |
5 | 20/35 (57%) | 0.50 | 1.01 (0.98–1.03) | 1.00 |
6 | 20/35 (57%) | 0.50 | 1.02 (0.97–1.07) | 1.00 |
7 | 25/35 (71%) | 0.02 | 1.04 (1.01–1.08) | 1.00 |
8 | 25/35 (71%) | 0.02 | 1.05 (1.01–1.09) | 0.99 |
9 | 19/35 (54%) | 0.74 | 1.00 (0.98–1.02) | 1.00 |